Wyeth discloses new CEO's salary
Wonder what a big cheese in Big Pharma earn these days? Well, Wyeth told the Securities & Exchange Commission that it plans to pay its new chief Bernard Poussot (photo) $1.5 million in base salary, plus 120,000 restricted stock units that start vesting in three years. Meanwhile, its non-employee directors will get $220,000 annually in 2008 and 2009.
Remember, though, that base pay is just that. According to Forbes, Wyeth's current CEO, Robert Essner, raked in $25.66 million in 2006, including base pay, bonuses, stock, and perks.
- read the AP report
- see the figures on Essner in Forbes
Related Articles:
Wyeth names Poussot CEO. Report
Wyeth stock down after several setbacks. Report
Wyeth CEO: FDA creating monopoly meds. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets